Daqing Xia

机构：University of Science and Technology of China

发表论文 14 篇 · 总被引 329 次 · h-index 9

代表论文

• Risk-adapted Treatment Strategy For COVID-19 Patients (2020 · International Journal of Infectious Diseases · 被引 94)
• Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial (2021 · Frontiers of Medicine · 被引 80)
• Neutrophil-to-Lymphocyte Ratios Are Closely Associated With the Severity and Course of Non-mild COVID-19 (2020 · Frontiers in Immunology · 被引 46)
• The efficacy of furazolidone and metronidazole in the treatment of chronic gastritis associated with Helicobacter (Campylobacter) pylori--a randomized double-blind placebo-controlled clinical trial. (1990 · PubMed · 被引 29)
• The performance of detecting Mycobacterium tuberculosis complex in lung biopsy tissue by metagenomic next-generation sequencing (2022 · BMC Pulmonary Medicine · 被引 18)
• Tocilizumab Ameliorates the Hypoxia in COVID-19 Moderate Patients with Bilateral Pulmonary Lesions: A Randomized, Controlled, Open-Label, Multicenter Trial (2020 · SSRN Electronic Journal · 被引 18)